Literature DB >> 18208819

Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.

Allan Wailoo, Nick Bansback, Jim Chilcott.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18208819     DOI: 10.1093/rheumatology/kem294

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  5 in total

1.  Release and activity of anti-TNFalpha therapeutics from injectable chitosan preparations for local drug delivery.

Authors:  Mohammed F Shamji; Priscilla Hwang; Robert W Bullock; Samuel B Adams; Dana L Nettles; Lori A Setton
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2009-07       Impact factor: 3.368

Review 2.  There's more to life than everyday function: the challenge of measuring social role participation in ankylosing spondylitis.

Authors:  Aileen M Davis; Rosalind Wong; Elizabeth M Badley; Monique A Gignac
Journal:  Nat Clin Pract Rheumatol       Date:  2009-01

Review 3.  Efficacy and safety of adalimumab in ankylosing spondylitis.

Authors:  Aziza Mounach; Abdellah El Maghraoui
Journal:  Open Access Rheumatol       Date:  2014-08-13

4.  Barriers to Oncology Biosimilars Uptake in the United States.

Authors:  Chadi Nabhan; Amy Valley; Bruce A Feinberg
Journal:  Oncologist       Date:  2018-07-26

5.  Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial.

Authors:  James Cheng-Chung Wei; Hsi-Kai Tsou; Pui-Ying Leong; Chia-Yin Chen; Jin-Xian Huang
Journal:  Front Med (Lausanne)       Date:  2020-10-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.